Biotech China 2014

Pharmacology: Bristol-Myers Squibb

Total Score People Score Events Score
10 10 7
Date Event Presentation Speakers
April 6, 2010 IBCs 5th Annual China 2010 Pharmaceutical R&D Summit 1 Key Factors to be Considered for Clinical Development in Emerging Markets Ruiping Dong
1 Chairperson's Opening Remarks Ruiping Dong
June 3, 2009 7th Annual QT Prolongation and Safety Pharmacology Assessing the risk of proarrythmia? Danshi Li
Assessing the risk of Na channel inhibition Danshi Li
February 23, 2009 Advances and Progress in Drug Design VIII p38 MAP KINASE INHIBITORS: A CASE STUDY IN STRUCTURE-BASED DRUG DESIGN Arthur M Doweyko
October 12, 2008 15th North American Regional Meeting - International Society for the Study of Xenobiotics Integrating ‘omics’ technologies into Safety Evaluation and Risk Assessment Lois-Lehman McKeeman
June 18, 2008 Accelerating Anticancer Agent Development and Validation Workshop Faculty Renzo Canetta, Giuseppe Giaccone, Ashok Batra
Panelists Renzo Canetta
May 30, 2008 ASCO Annual'08 Meeting clinical trials-- Choice of Comparator in Pivotal Phase III Clinical Trials: Clinical Versus Regulatory Standard of Care Steven D. Averbuch
clinical trials-- Endpoints for Immunotherapy Studies: Design and Regulatory Implications Axel Hoos
international-- Choice of Comparator in Pivotal Phase III Clinical Trials: Clinical Versus Regulatory Standard of Care Steven D. Averbuch
tumor biology-- Endpoints for Immunotherapy Studies: Design and Regulatory Implications Axel Hoos
October 11, 2007 Compound Profiling & Chemogenomic Approaches to Drive Decision Making and Predict Clinical Adverse Effects (Oct 11-12) SELECTING LEADS AND DETECTING ADVERSE ACTIVITY: Characterizing the Multiple Activities of Kinase Inhibitors (15:05-15:35) Petra Ross-Macdonald
SELECTING LEADS AND DETECTING ADVERSE ACTIVITY (14:00-17:30) Petra Ross-Macdonald
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.